CL
Celldex Therapeutics, Inc.
CLDX · NASDAQ
$33.51 -8.44% (-$3.09)
1M -17.40%
Market Cap $2.52B
P/E Ratio -
Div. Yield -
ROE 52.36%
Bulios Fair Price
$20.37
39.2% downside
Current Price
$33.51
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLDX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
29 /100
Expensive P/S 22,510.20x
P/B 3.53x
P/E N/A
Growth
22 /100
Declining Rev. growth 13.98%
Book val. growth 17.35%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 56,850.90%
Net margin 268,386.00%
Op. margin 290,948.00%
Quality
0 /100
Poor ROIC 45.10%
ROE 52.36%
ROA 38.42%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 11.82x
Int. coverage N/A
Stability
42 /100
Moderate Beta 0.84x
Rev. volatility 138.96%
EPS volatility 37.64%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Anthony S. Marucci
Employees
198
Headquarters
Hampton
Upcoming events
09 NOV
Earnings
Upcoming earnings report